Pharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosin
Inventors
Ryu, Jong Hoon • Lee, Hyung Eun • Kang, Sam Sik • Kim, Ju Sun • Lee, So Young • Kim, Do Hoon • Kim, Dong Sup • Kim, Seung Hee
Assignees
MINISTRY OF FOOD AND DRUG SAFETY • Daehwa Pharmaceutical Co Ltd
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9956242-B2
Publication Date
2018-05-01
Expiration Date
Abstract
The pharmaceutical composition of the present invention, which comprises spinosin or a spinosin-containing herbal extract, is a composition for preventing and treating cognitive function disorders, and can effectively improve memory and learning ability, and effectively treat and prevent cognitive function disorders such as dementia and amnesia.
Core Innovation
The disclosure provides spinosin and spinosin-containing herbal extracts as active ingredients for pharmaceutical compositions used to prevent and treat cognitive impairments, including dementia and amnesia. Cognitive impairments include Alzheimer’s disease, vascular dementia, and degenerative brain diseases. The disclosure describes a spinosin chemical structure and provides sourcing and extraction options for obtaining spinosin or spinosin-containing extracts.
The disclosure includes pharmaceutical compositions comprising spinosin or a pharmaceutically acceptable salt of spinosin, and example formulations including powders, tablets, capsules, injections, liquid formulations, and health foods and beverages. The disclosure states additive and excipient components and administration routes in connection with pharmaceutical compositions comprising spinosin or spinosin-containing herbal extracts.
The disclosure reports animal model efficacy for spinosin in scopolamine-induced memory impairment and describes improved learning and memory metrics from passive avoidance, Y-maze, and Morris water maze tests. The reported results include comparisons to donepezil. The disclosure describes spinosin sources as spinosin-containing herbal extracts, preferably from Zizyphus jujuba Mill var. spinosa seeds, and also lists additional herbal extracts that can be used with spinosin in the pharmaceutical compositions.
Claims Coverage
Independent claims clm-00001 and clm-00003 define dementia treatment by administering, to a subject in need, a pharmaceutical composition containing spinosin, with clm-00003 further requiring at least one specified botanical extract. The claim set therefore centers on two inventive feature themes: spinosin or a pharmaceutically acceptable salt as an active ingredient for dementia treatment, and dementia treatment with spinosin plus specified selected extracts.
Dementia treatment with spinosin or a pharmaceutically acceptable salt
Administering, in an amount effective to treat dementia to a subject in need, a pharmaceutical composition comprising spinosin or a pharmaceutically acceptable salt thereof, as an active ingredient.
Dementia treatment with spinosin plus at least one selected herbal extract
Administering, in an amount effective to treat dementia to a subject in need, a pharmaceutical composition comprising spinosin, wherein the pharmaceutical composition comprises at least one selected from the group consisting of an extract of Zizyphus jujuba Mill var. inermis, an extract of Zizyphus jujuba Mill var. hoonensis, an extract of Zizyphus jujuba Mill var. spinosa, an extract of Passiflora edulis flavicarpa, an extract of Cayaponia tayuya, an extract of Desmodium tortuosum, an extract of Wilbrandia ebracteata, an extract of Strophioblachia fimbricalyx, an extract of Clutia abyssinica, and an extract of Saccharopolyspora spinosa.
Across the independent claims, the core claim coverage is a method of treating dementia by administering a pharmaceutically effective composition containing spinosin, optionally as a pharmaceutically acceptable salt, and in the broader inventive framework also including at least one specified herbal extract selected from a defined group.
Stated Advantages
Treating dementia.
Improved learning and memory in scopolamine-induced memory impairment model (compared with donepezil).
Documented Applications
Preventing and treating cognitive impairments such as dementia and amnesia, including Alzheimer’s disease and vascular dementia.
Using spinosin in a scopolamine-induced memory impairment animal model to evaluate learning and memory using passive avoidance, Y-maze, and Morris water maze tests.
Formulating spinosin or spinosin-containing herbal extracts into pharmaceutical compositions such as powders, tablets, capsules, injections, liquid formulations, and health foods and beverages.
Interested in licensing this patent?